Gene: GLIS3

169792
NDH|ZNF515
GLIS family zinc finger 3
protein-coding
9p24.2
Ensembl:ENSG00000107249 MIM:610192 Vega:OTTHUMG00000019463 UniprotKB:Q8NEA6
NG_011782.1
PubMed|SNP Mapped
2   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.519e-1 (AD)  9.707e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12348139chr9:4232743 (GRCh38.p7)T>Cnicotine dependenceSNV(Single Nucleotide Variation)
rs7851070chr9:4170457 (GRCh38.p7)A>Gnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
YAP10.841
PALLD0.834
SRGAP10.83
NEK60.828
ASAP30.823
LRP100.822
TNFRSF1A0.821
RFX40.82
SLC44A30.82
FERMT20.812

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SLC7A4-0.516
ABCC12-0.51
MYOZ3-0.51
MYCNOS-0.508
LHX6-0.501
AARD-0.498
PPEF1-0.488
CRHBP-0.484
KCNS3-0.481
SAMD5-0.481

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of GLIS3 mRNA29067470
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of GLIS3 gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of GLIS3 mRNA27153756
D017638Asbestos, Crocidolite"Asbestos, Crocidolite affects the expression of GLIS3 mRNA"17331233
C547126AZM551248AZM551248 results in increased expression of GLIS3 mRNA22323515
C487081belinostatbelinostat results in decreased expression of GLIS3 mRNA26272509
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of GLIS3 mRNA20064835|2010694
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of GLIS3 mRNA19770486
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of GLIS3 mRNA27195522
D004958EstradiolEstradiol results in increased expression of GLIS3 mRNA20106945
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of GLIS3 mRNA17484886
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of GLIS3 mRNA26272509
D016572CyclosporineCyclosporine results in decreased expression of GLIS3 mRNA27989131
D016572CyclosporineCyclosporine results in increased expression of GLIS3 mRNA20106945
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of GLIS3 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of GLIS3 mRNA27392435
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of GLIS3 mRNA24535843
C118739entinostatentinostat results in decreased expression of GLIS3 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C045651epigallocatechin gallateepigallocatechin gallate results in increased expression of GLIS3 mRNA22079256
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLIS3 mRNA22079256
D007213IndomethacinIndomethacin results in increased expression of GLIS3 mRNA28201806
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of GLIS3 mRNA27392435
C544151jinfukangjinfukang results in decreased expression of GLIS3 mRNA27392435
D007854LeadLead affects the expression of GLIS3 mRNA28903495
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of GLIS3 mRNA"24972896
C042720mercuric bromidemercuric bromide results in decreased expression of GLIS3 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of GLIS3 mRNA28001369
D009532NickelNickel results in increased expression of GLIS3 mRNA24768652|2558310
C029938nickel sulfatenickel sulfate results in decreased expression of GLIS3 mRNA22714537
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of GLIS3 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of GLIS3 mRNA26272509
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLIS3 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of GLIS3 mRNA22079256|2271453
C513428pyrachlostrobinpyrachlostrobin results in increased expression of GLIS3 mRNA27029645
D012834SilverSilver results in increased expression of GLIS3 mRNA27131904
C017947sodium arsenitesodium arsenite results in decreased expression of GLIS3 mRNA22714537
D000952Antigens, Polyomavirus Transforming"Antigens, Polyomavirus Transforming results in decreased expression of GLIS3 mRNA"26680231
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of GLIS3 mRNA24058054
D014212TretinoinTretinoin results in decreased expression of GLIS3 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of GLIS3 mRNA24935251|2627250
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of GLIS3 mRNA"26179874
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of GLIS3 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of GLIS3 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in decreased methylation of GLIS3 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of GLIS3 mRNA23179753|2718838
D014635Valproic AcidValproic Acid affects the expression of GLIS3 mRNA17292431
D014638VanadatesVanadates results in increased expression of GLIS3 mRNA22714537
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of GLIS3 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0003677DNA binding-IEA-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-ISS-  
GO:0006366transcription by RNA polymerase II-ISS-  
GO:0045944positive regulation of transcription by RNA polymerase II-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-ISS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28440896Genome-wide meta-analysis identifies a novel susceptibility signal at CACNA2D3 for nicotine dependence. (2017 Apr 25)Yin XAm J Med Genet B Neuropsychiatr Genet